GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Beyond Brain Plaques: How "Super-Ager" Brain Signals, Non-Amyloid Pills, and Generative AI Care Tech Are Redefining Alzheimer’s in November 2026
Explore the November 2026 Alzheimer's breakthroughs from CTAD 2026 and HLTH USA. Discover Stanford's "super-ager" brain signal scoring, non-amyloid oral trials like AR1001 and diranersen, and AI-powered caregiving innovations.
Navigating Every Stage with Dignity: How New National Care Models, Validation Strategies, and Hospice Checklists Are Transforming Alzheimer’s Support in 2026
Learn how late-2026 patient care initiatives, CMS GUIDE dementia support programs, compassionate validation strategies, and structured hospice transition checklists help families navigate every stage of Alzheimer's with dignity and confidence.
Beyond the Memory Fog: How DNA-Repair Pills, Brainshuttle Trials, and Ambient Sensing are Reshaping Global Alzheimer’s Care
Explore the latest November 2026 Alzheimer's breakthroughs. Discover oral DNA-repair treatments, Brainshuttle antibody clinical trials, community blood tests, and non-intrusive smart home tech easing the caregiving and hospice journey.
Beyond the Plaque Paradigm: How Blood Tests, Immune Therapies, and Smart Sensing Are Transforming Global Alzheimer’s Care in 2026
Explore late-October 2026 Alzheimer's research breakthroughs. Discover how high-accuracy blood tests, microglial sleep discoveries, and passive home-sensing healthtech are revolutionizing dementia care and hospice support worldwide.
The Expanding Horizon: Democratization and Evolving Landscapes in Medical Clinical Trials
This essay explores the latest developments in this ongoing transformation, highlighting the key drivers, emerging trends, and potential challenges in creating a more equitable and efficient clinical trial ecosystem.
The Looming Alzheimer's Crisis: Projecting the Burden in the United States by 2060
This essay examines the current estimates of Alzheimer's patients in the US, particularly focusing on projections to 2060, analyzing the factors contributing to this impending crisis and discussing the implications for future research, policy, and resource allocation.
Advances in Neurological Disease Detection: A New Era of Precision and Early Intervention
Neurological diseases, encompassing a vast spectrum of disorders affecting the brain, spinal cord, and peripheral nerves, pose a significant and growing global health challenge. Conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke not only inflict immense personal suffering but also place a substantial burden on healthcare systems
The Unseen Risk: Navigating the Perilous Path of Clinical Trials
The relentless march of medical advancement is a beacon of hope for millions, a testament to humanity's unyielding desire to conquer disease and extend life. At the forefront of this crusade stands the clinical trial, the crucible in which experimental treatments are rigorously tested. While these trials are often hailed as pivotal steps toward groundbreaking therapies, it is imperative to acknowledge the stark and sometimes devastating reality: participation in clinical trials can carry life-threatening consequences. Beyond the statistics and scientific jargon
Battling Alzheimer's: A New Hope on the Horizon
Alzheimer's Disease. The very name evokes a sense of dread, a long, slow fading of memory, personality, and ultimately, life itself. It's a condition that not only devastates those who suffer from it but also places an immense emotional and physical burden on their families and caregivers. For years, the scientific and medical communities have been locked in a relentless battle against this formidable foe, striving to understand its origins, slow its progression, and ideally, find a cure.
INmune Bio: Alzheimer’s Trial Results and Stock Shock
The recent news surrounding INmune Bio has sent ripples through the biotechnology investment world, causing the company's stock to plummet by over 50%. This dramatic drop wasn't due to a scandal or financial mismanagement, but rather the outcome of a clinical trial for their Alzheimer's disease drug, XPro.
Triumphant Return: Judge Orders FDA to Restore Vital Clinical Trial Diversity Webpages, Empowering Health Equity!
It is a truly hopeful and significant development in the realm of healthcare and government transparency that a US District Judge has recently ordered the full reinstatement of crucial healthcare resources, including vital webpages dedicated to clinical trial diversity, by the US Food and Drug Administration (FDA) and the Department of Health and Human Services
Stay Steady, Stay Safe: The Ultimate Guide to Preventing Falls and Fractures as You Age
For many older adults, a simple everyday mishap—like slipping on a wet floor or tripping over a rug—can instantly become a life-altering event. Falls are not just common; they are a significant threat to long-term health, mobility, and independence. Every year, thousands of older adults experience broken bones due to falls.
A Simple Blood Test Revolutionizes Alzheimer's Care: Why Roche's FDA Greenlight Changes Everything
The landscape of Alzheimer’s disease diagnosis and treatment is on the cusp of a dramatic transformation, thanks to the recent US Food and Drug Administration (FDA) clearance of a novel blood-based test developed by Roche. This approval is not just another step in medical technology; it signifies a potential "care paradigm shift" by introducing a simple, accessible tool that can efficiently evaluate the risk of Alzheimer’s disease pathology, particularly in primary care settings.
Remote Relief: How Virtual Support Boosts Mood and Confidence for Families Facing Dementia
Dementia is a health crisis sweeping the globe. Experts estimate that roughly 50 million people worldwide are currently living with this condition. That enormous figure is expected to nearly double to 80 million by 2030 and potentially surpass 150 million by 2050. Alarmingly, a new dementia diagnosis happens every three seconds.
The Titans of Memory: Inside the Top 7 Organizations Fighting Alzheimer’s Disease
Alzheimer’s research in the United States is a massive, multi-billion-dollar ecosystem. It is led by a powerful and highly coordinated mix of federal government agencies, non-profit foundations, and elite academic medical centers.
Beyond the Memory Trap: Simple Blood Tests, Subcut Injections, and Smart Care Tech are Rewriting the Alzheimer’s Story
Explore the latest 2026 Alzheimer’s research updates. Discover how simple blood tests, new home-injection trials, AI healthtech, and modern caregiving strategies are transforming memory care and hospice support.
Beyond the "Black Box": Why Trust is the Ultimate Data Moat in Clinical Trial Recruitment
In the high-stakes world of clinical research, fixed machine learning models face a silent, inevitable threat: drift. As clinical practices shift, lab equipment is recalibrated, and patient populations evolve, static algorithms slowly degrade in accuracy. At Glassbury, we recognize that a "black box" approach is insufficient for the long-term challenges of Alzheimer's disease and related CNS conditions
The Blood Test "Smoke Detector": How AI Helps Family Doctors Spot Alzheimer’s Early
For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps. This delay is particularly challenging in primary care, where family doctors
Why We Can't Sleep in Early Alzheimer's: The New Science of Brain Inflammation
For years, we have known that people with early-stage Alzheimer’s often struggle to get a good night's rest. For a long time, scientists thought this was simply because of "plaques"—sticky protein buildups called amyloid—clogging up the brain.
Bridging the Gap: How Glassbury AI is Making Medical Research Work for Everyone
At Glassbury AI, we believe health justice starts with inclusion. We are using modern technology to fix this recruitment crisis by building trust and making the process easy to understand for every family.